Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24701663 | 0.78 | CYP1A2 (0.35) | KMT2AMAPTKDM4EMEN1MAPK1 | |
| SCHEMBL564222 | 0.77 | NOTUM (0.36) | KMT2AMAPTKDM4EMEN1MAPK1 | |
| SCHEMBL14392799 | 0.74 | PDK2 (0.33) | KMT2AMAPTKDM4EMEN1MAPK1 | |
| SCHEMBL676795 | 0.74 | PDK2 (0.38) | MAPTKDM4ELMNAHTTPDK2 | |
| SCHEMBL24701900 | 0.72 | KMT2A (0.37) | KMT2AMAPTKDM4EMEN1LMNA | |
| SCHEMBL15614854 | 0.71 | AKR1B1 (0.35) | KMT2AMAPTMEN1 | |
| SCHEMBL15428009 | 0.70 | SRD5A1 (0.38) | KMT2AMAPTKDM4EMEN1MAPK1 | |
| SCHEMBL13297894 | 0.70 | PGR (0.40) | KMT2AKDM4EMEN1MAPK1LMNA | |
| SCHEMBL9157168 | 0.70 | SMN1; SMN2 (0.33) | KMT2AMAPTKDM4EMEN1MAPK1 | |
| SCHEMBL11981166 | 0.69 | PDK2 (0.37) | KMT2AMAPTMEN1ALDH1A1PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917901-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20220393115-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-11005050-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-05-11 | — | — | US | disclosed |
| EP-3424936-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2021-04-07 | — | — | EP | disclosed |
| US-10563000-B2 | Low-temperature radical polymerisation of alkoxyamines | ARKEMA FRANCE (FR) | 2020-02-18 | — | — | US | disclosed |
| US-20190048118-A1 | LOW-TEMPERATURE RADICAL POLYMERISATION OF ALKOXYAMINES | ARKEMA FRANCE (FR) | 2019-02-14 | — | — | US | disclosed |
| EP-3424936-A1 | METAL COMPLEXES | Merck Patent GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-9837622-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2017-12-05 | — | — | US | disclosed |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080146737-A1 | THERMOPLASTIC ELASTOMER COMPOSITION | THE YOKOHAMA RUBBER CO., LTD. (JP) | 2008-06-19 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | KMT2A 3491/4885MAPT 3311/4885KDM4E 1626/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | KMT2A 4066/4885MAPT 4102/4885KDM4E 2403/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | KMT2A 4302/4885MAPT 3286/4885KDM4E 3076/4885 |
| US-11005050-B2 | Metal complexes | SOD1, AP1M1, AP3M1 | KMT2A 2922/4885MAPT 1084/4885KDM4E 3816/4885 |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NOS1, NOS3, NOS2 | KMT2A 3390/4885MAPT 4788/4885KDM4E 1815/4885 |
| US-20220393115-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | LEF1, L1CAM, PIEZO1 | KMT2A 2084/4885MAPT 2059/4885KDM4E 2556/4885 |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | PTGIS, F3, PTGIR | KMT2A 4266/4885MAPT 4696/4885KDM4E 2235/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | KMT2A 3084/4885MAPT 2700/4885KDM4E 2614/4885 |
| US-11917901-B2 | Metal complexes | MCOLN2, MCOLN1, AP1M1 | KMT2A 1876/4885MAPT 2472/4885KDM4E 4260/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | KMT2A 4143/4885MAPT 3188/4885KDM4E 1236/4885 |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | KMT2A 4371/4885MAPT 3675/4885KDM4E 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.